Radius Health Inc. (NASDAQ:RDUS) shares were up 3.8% during trading on Thursday . The stock traded as high as $43.39 and last traded at $42.98, with a volume of 347,583 shares changing hands. The stock had previously closed at $41.39.

Several research analysts have commented on RDUS shares. Goldman Sachs Group Inc. started coverage on shares of Radius Health in a report on Wednesday, March 30th. They set a “neutral” rating and a $37.00 price objective for the company. Cantor Fitzgerald reissued a “buy” rating and set a $70.00 price objective on shares of Radius Health in a report on Thursday, March 31st. Canaccord Genuity reissued a “buy” rating on shares of Radius Health in a report on Monday, April 4th. Zacks Investment Research downgraded shares of Radius Health from a “hold” rating to a “sell” rating in a report on Tuesday, April 26th. Finally, Cowen and Company started coverage on shares of Radius Health in a report on Friday, May 6th. They set an “outperform” rating for the company. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Radius Health has an average rating of “Buy” and a consensus price target of $70.07.

The firm has a 50 day moving average price of $37.95 and a 200-day moving average price of $35.45. The stock’s market cap is $1.82 billion.

Radius Health (NASDAQ:RDUS) last released its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by $0.20. The company’s revenue was up .0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.47) EPS. On average, equities research analysts predict that Radius Health Inc. will post ($3.71) earnings per share for the current fiscal year.

Other hedge funds and institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP purchased a new position in Radius Health during the fourth quarter worth $1,362,000. Wells Fargo & Company MN boosted its position in Radius Health by 7.5% in the fourth quarter. Wells Fargo & Company MN now owns 422,217 shares of the biopharmaceutical company’s stock worth $25,984,000 after buying an additional 29,601 shares during the last quarter. Mutual of America Capital Management LLC boosted its position in Radius Health by 18.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 36,483 shares of the biopharmaceutical company’s stock worth $2,245,000 after buying an additional 5,683 shares during the last quarter. New York State Common Retirement Fund boosted its position in Radius Health by 36.0% in the fourth quarter. New York State Common Retirement Fund now owns 69,048 shares of the biopharmaceutical company’s stock worth $4,249,000 after buying an additional 18,259 shares during the last quarter. Finally, ProShare Advisors LLC boosted its position in Radius Health by 9.7% in the fourth quarter. ProShare Advisors LLC now owns 40,595 shares of the biopharmaceutical company’s stock worth $2,498,000 after buying an additional 3,574 shares during the last quarter.

Radius Health, Inc is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, oncology and endocrine diseases. The Company’s lead product candidate is the investigational drug abaloparatide for subcutaneous injection (abaloparatide-SC), which has completed Phase III development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.